Literature DB >> 17341565

Effects of testosterone treatment on endometrial proliferation in postmenopausal women.

Hong Zang1, Lena Sahlin, Britt Masironi, Elina Eriksson, Angelica Lindén Hirschberg.   

Abstract

CONTEXT: Available data concerning effects of testosterone on endometrium of postmenopausal women are seriously limited.
OBJECTIVE: Our aim was to compare the influence of treatment with testosterone and/or estrogen on endometrial proliferation in healthy postmenopausal women.
DESIGN: This was an open, randomized clinical study with parallel comparison of the groups.
SETTING: The study was conducted at a women's health clinical research unit and a research laboratory at a university hospital. PARTICIPANTS: Sixty-three women who had experienced natural menopause participated in this study.
INTERVENTIONS: After random assignment, the participants were administered orally testosterone undecanoate (40 mg every second day), estradiol valerate (2 mg daily), or both for 3 months. MAIN OUTCOME MEASURES: Endometrial thickness was measured, and endometrial proliferation evaluated on the basis of histopathology and expression of Ki-67, a proliferation marker.
RESULTS: Endometrial thickness was significantly increased by treatment with estrogen alone or in combination with testosterone but was unaltered by testosterone alone. Among the women receiving estrogen alone, the proportion exhibiting histopathology indicative of proliferation increased significantly to 50% (P < 0.05), there was a nonsignificant increase to 28% with the combined treatment, whereas testosterone alone had no effect at all. Expression of Ki-67 was up-regulated significantly in both glands and stroma (P < 0.05, respectively) in both estrogen treatment groups. However, the expression was significantly higher in stroma by estrogen treatment alone than after combined treatment (P < 0.05).
CONCLUSIONS: The short-term treatment with testosterone of postmenopausal women does not stimulate endometrial proliferation. In addition, testosterone appears to counteract endometrial proliferation induced by estrogen to a certain extent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341565     DOI: 10.1210/jc.2006-2171

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study.

Authors:  Tess V Clendenen; Kathryn Hertzmark; Karen L Koenig; Eva Lundin; Sabina Rinaldi; Theron Johnson; Vittorio Krogh; Göran Hallmans; Annika Idahl; Annekatrin Lukanova; Anne Zeleniuch-Jacquotte
Journal:  Horm Cancer       Date:  2016-02-29       Impact factor: 3.869

2.  Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate.

Authors:  Christiane Otto; Iris Fuchs; Helga Altmann; Mario Klewer; Alexander Walter; Katja Prelle; Richardus Vonk; Karl-Heinrich Fritzemeier
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

3.  Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone.

Authors:  Charles E Wood; Cynthia J Lees; J Mark Cline
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

Review 4.  Androgen replacement therapy in androgen-deficient women with hypopituitarism.

Authors:  Hong Zang; Susan R Davis
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus.

Authors:  Ioannis Simitsidellis; Arantza Esnal-Zuffiaure; Olympia Kelepouri; Elisabeth O'Flaherty; Douglas A Gibson; Philippa T K Saunders
Journal:  J Endocrinol       Date:  2019-09       Impact factor: 4.286

6.  Differential Expression of Androgen Receptor in Type I and Type II Endometrial Carcinomas: A Clinicopathological Analysis and Correlation with Outcome.

Authors:  Nisreen Abu Shahin; Tariq Aladily; Nezeen Abu Alhaj; Ali Al-Khader; Shefa Alqaqa; Reyad Aljaberi; Lama Amer; Sanad Elshebli
Journal:  Oman Med J       Date:  2021-03-31

7.  A Gigantic Uterine Leiomyoma and Big Bilateral Adrenal Myelolipomas as a Result of Untreated Congenital Adrenal Hyperplasia.

Authors:  Betty La; Celestine Tung; Eugene A Choi; Ha Nguyen
Journal:  AACE Clin Case Rep       Date:  2021-05-13

8.  A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xing-Wei Liang; Zhen-Bo Wang; Zhao-Yi Wang; Jie Qiao; Heide Schatten; Qing-Yuan Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-09-24       Impact factor: 5.211

9.  Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.

Authors:  A M Kamal; J N Bulmer; S B DeCruze; H F Stringfellow; P Martin-Hirsch; D K Hapangama
Journal:  Br J Cancer       Date:  2016-03-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.